Bill Detail
H.R. 1492
Congress: 119
Title
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Summary
This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation. The bill's changes apply retroactively.
Sponsor
Rep. Gregory Murphy [R-NC-3]
Status
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Status as of Aug 3, 3:14 AM · synced 11d ago
Introduced
2025-02-21
Data source mode: congress-gov
Bill Engagement
This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negot…
Lobbyists on the case
- Pharmaceutical Research and Manufacturers of America5 filings · 28 lobs
- Teresa Bill2026 Q1
- Elenora Connors2026 Q1
Prepared intelligence brief
Put this record in the joined picture.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.